COR Quote, Financials, Valuation and Earnings

Cardinal Health has a net margin of 0% compared to Cencora's net margin of 0.8%. Cencora's return on equity of 157.14% beat Cardinal Health's return on equity of --.

Cencora has a consensus price target of $266.34, signalling upside risk potential of 17.05%. On the other hand Cardinal Health has an analysts' consensus of $129.74 which suggests that it could grow by 9.18%. Given that Cencora has higher upside potential than Cardinal Health, analysts believe Cencora is more attractive than Cardinal Health.

Cencora has a beta of 0.455, which suggesting that the stock is 54.467% less volatile than S&P 500. In comparison Cardinal Health has a beta of 0.611, suggesting its less volatile than the S&P 500 by 38.904%.

Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.91%. Cardinal Health offers a yield of 1.69% to investors and pays a quarterly dividend of $0.51 per share. Cencora pays 27.58% of its earnings as a dividend. Cardinal Health pays out 58.57% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora quarterly revenues are $79.1B, which are larger than Cardinal Health quarterly revenues of $52.3B. Cencora's net income of $3.4M is lower than Cardinal Health's net income of $416M. Notably, Cencora's price-to-earnings ratio is 30.30x while Cardinal Health's PE ratio is 23.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.16x versus 0.13x for Cardinal Health. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of 0% compared to Cencora's net margin of 0.26%. Cencora's return on equity of 157.14% beat McKesson's return on equity of --.

Cencora has a consensus price target of $266.34, signalling upside risk potential of 17.05%. On the other hand McKesson has an analysts' consensus of $653.95 which suggests that it could grow by 12.92%. Given that Cencora has higher upside potential than McKesson, analysts believe Cencora is more attractive than McKesson.

Cencora has a beta of 0.455, which suggesting that the stock is 54.467% less volatile than S&P 500. In comparison McKesson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 51.023%.

Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.91%. McKesson offers a yield of 0.46% to investors and pays a quarterly dividend of $0.71 per share. Cencora pays 27.58% of its earnings as a dividend. McKesson pays out 10.46% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora quarterly revenues are $79.1B, which are smaller than McKesson quarterly revenues of $93.7B. Cencora's net income of $3.4M is lower than McKesson's net income of $241M. Notably, Cencora's price-to-earnings ratio is 30.30x while McKesson's PE ratio is 29.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.16x versus 0.23x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

Pineapple has a net margin of 0% compared to Cencora's net margin of --. Cencora's return on equity of 157.14% beat Pineapple's return on equity of --.

Cencora has a consensus price target of $266.34, signalling upside risk potential of 17.05%. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Cencora has higher upside potential than Pineapple, analysts believe Cencora is more attractive than Pineapple.

Cencora has a beta of 0.455, which suggesting that the stock is 54.467% less volatile than S&P 500. In comparison Pineapple has a beta of 28.578, suggesting its more volatile than the S&P 500 by 2757.84%.

Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.91%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cencora pays 27.58% of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora quarterly revenues are $79.1B, which are larger than Pineapple quarterly revenues of --. Cencora's net income of $3.4M is higher than Pineapple's net income of --. Notably, Cencora's price-to-earnings ratio is 30.30x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.16x versus 70.72x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.

Zomedica has a net margin of 0% compared to Cencora's net margin of -95.71%. Cencora's return on equity of 157.14% beat Zomedica's return on equity of -27.17%.

Cencora has a consensus price target of $266.34, signalling upside risk potential of 17.05%. On the other hand Zomedica has an analysts' consensus of -- which suggests that it could grow by 108.33%. Given that Zomedica has higher upside potential than Cencora, analysts believe Zomedica is more attractive than Cencora.

Cencora has a beta of 0.455, which suggesting that the stock is 54.467% less volatile than S&P 500. In comparison Zomedica has a beta of 1.044, suggesting its more volatile than the S&P 500 by 4.385%.

Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.91%. Zomedica offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cencora pays 27.58% of its earnings as a dividend. Zomedica pays out -- of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora quarterly revenues are $79.1B, which are larger than Zomedica quarterly revenues of $7M. Cencora's net income of $3.4M is higher than Zomedica's net income of -$6.7M. Notably, Cencora's price-to-earnings ratio is 30.30x while Zomedica's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.16x versus 4.40x for Zomedica. Usually stocks with elevated PS ratios are considered overvalued.